Rizwan Velji
Managing Director, Biopharma
About Mr. Velji
Rizwan Velji is a managing director based in William Blair’s New York office. He joined the firm's investment banking team in 2021. Prior to William Blair, he worked for Citigroup and Lazard.
Notable Transactions
- Karuna Therapeutics - initial public offering and follow on offerings
- PTC Therapeutics - follow on and convertible offerings
- Loxo Oncology - follow on offerings
- Apellis - initial public offering
- Gelesis - de-SPAC and PIPE financing
- Everest Medicines - initial public offering
- Sun Pharma - acqusition of Ranbaxy Holdings
- CRISPR Therapeutics - initial public offering
- Bristol Myers - acquisition of Amylin and Inhibitex
Rigorous pursuit of your success. Every transaction. Every time.
Our investment bankers are 100 percent committed to your organization’s sustained success. By drawing on our deep industry and product experience as well as our dedicated global resources, we provide advisory and financing services that allow you to capitalize on today’s opportunities and anticipate tomorrow’s challenges.
More about investment banking at William Blair
Biopharma
The rapid and cost-effective development of innovative therapeutics and treatments is critical not just to public health, but to the functioning of society and economic activity. Leading drug developers, as well as their partners across the research, development, and manufacturing value chain, count on William Blair’s deep expertise in biopharma’s capital-raising and deal-making landscape.
More about our biopharma expertise
About William Blair
William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
Year William Blair was founded
Employees worldwide
Client assets
Independent and employee-owned
Offices worldwide
Companies under coverage
As of March 31, 2022
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.